PL3236960T3 - Fluralaner do zastosowania w leczeniu demodekozy - Google Patents
Fluralaner do zastosowania w leczeniu demodekozyInfo
- Publication number
- PL3236960T3 PL3236960T3 PL15817303.9T PL15817303T PL3236960T3 PL 3236960 T3 PL3236960 T3 PL 3236960T3 PL 15817303 T PL15817303 T PL 15817303T PL 3236960 T3 PL3236960 T3 PL 3236960T3
- Authority
- PL
- Poland
- Prior art keywords
- demodicosis
- fluralaner
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199562 | 2014-12-22 | ||
| PCT/EP2015/080744 WO2016102437A1 (en) | 2014-12-22 | 2015-12-21 | Use of isoxazoline compounds for treating demodicosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3236960T3 true PL3236960T3 (pl) | 2025-07-07 |
Family
ID=52146273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15817303.9T PL3236960T3 (pl) | 2014-12-22 | 2015-12-21 | Fluralaner do zastosowania w leczeniu demodekozy |
| PL21213190.8T PL4008329T3 (pl) | 2014-12-22 | 2015-12-21 | Związki izoksazoliny do zastosowania w leczeniu demodekozy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21213190.8T PL4008329T3 (pl) | 2014-12-22 | 2015-12-21 | Związki izoksazoliny do zastosowania w leczeniu demodekozy |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170348286A1 (enExample) |
| EP (3) | EP4008329B1 (enExample) |
| JP (1) | JP6706262B2 (enExample) |
| CN (2) | CN106999475B (enExample) |
| AU (3) | AU2015371175B2 (enExample) |
| BR (1) | BR112017013286A2 (enExample) |
| CA (1) | CA2971296A1 (enExample) |
| DK (2) | DK4008329T3 (enExample) |
| ES (2) | ES3037078T3 (enExample) |
| FI (2) | FI3236960T3 (enExample) |
| PL (2) | PL3236960T3 (enExample) |
| PT (2) | PT3236960T (enExample) |
| RU (1) | RU2709198C2 (enExample) |
| WO (1) | WO2016102437A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| CA2971296A1 (en) | 2014-12-22 | 2016-06-30 | Intervet International B.V. | Use of isoxazoline compounds for treating demodicosis |
| WO2018039508A1 (en) * | 2016-08-25 | 2018-03-01 | Merial, Inc. | Method for reducing unwanted effects in parasiticidal treatments |
| CN107501199A (zh) * | 2017-08-16 | 2017-12-22 | 南京农业大学 | 氟雷拉纳单体化合物的提取和纯化方法 |
| CN119157876A (zh) * | 2017-12-15 | 2024-12-20 | 塔苏斯制药有限公司 | 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| US11880349B2 (en) | 2019-04-30 | 2024-01-23 | Salesforce, Inc. | System or method to query or search a metadata driven distributed ledger or blockchain |
| MX2022007455A (es) | 2019-12-18 | 2022-08-15 | Elanco Tiergesundheit Ag | Derivados de isoxazolina como plaguicidas. |
| JP7724845B2 (ja) | 2020-07-24 | 2025-08-18 | エランコ・ユーエス・インコーポレイテッド | イソオキサゾリン化合物及びその中間体を作製するための方法 |
| KR20230061465A (ko) | 2020-09-04 | 2023-05-08 | 엘랑코 유에스 인코포레이티드 | 기호성 제형 |
| CN115785017B (zh) * | 2022-12-06 | 2023-12-08 | 海利尔药业集团股份有限公司 | 一种取代的苯酰胺异噁唑啉衍生物或其作为农药可接受的盐、组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067863C1 (ru) * | 1994-05-25 | 1996-10-20 | Казанский государственный технологический университет | Акарицидный состав для лечения чесотки домашних животных |
| CN101768129B (zh) | 2004-03-05 | 2012-05-23 | 日产化学工业株式会社 | 异*唑啉取代苯甲酰胺化合物的制备中间体 |
| DE102004053964A1 (de) * | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Mittel gegen Demodikose |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| HUE037127T2 (hu) | 2007-06-27 | 2018-08-28 | Du Pont | Állati károkozó irtására szolgáló eljárás |
| TWI556741B (zh) * | 2007-08-17 | 2016-11-11 | 英特威特國際股份有限公司 | 異唑啉組成物及其作為抗寄生蟲藥上的應用 |
| TWI411395B (zh) | 2007-12-24 | 2013-10-11 | Syngenta Participations Ag | 殺蟲化合物 |
| EP2379544B1 (en) | 2008-12-18 | 2013-10-16 | Novartis AG | Isoxazolines derivatives and their use as pesticide |
| PL2379537T3 (pl) * | 2008-12-19 | 2013-03-29 | Elanco Tiergesundheit Ag | Pochodne izooksazoliny i ich zastosowanie jako pestycydów |
| CN103260620A (zh) | 2010-12-27 | 2013-08-21 | 英特维特国际股份有限公司 | 包含三缩四乙二醇的外用局部异噁唑啉制剂 |
| NZ611476A (en) | 2010-12-27 | 2015-10-30 | Intervet Int Bv | Topical localized isoxazoline formulation |
| SI2683723T1 (sl) | 2011-03-10 | 2016-07-29 | Zoetis Services Llc | Spirociklični izoksazolinski derivati kot antiparazitiki |
| PT3172964T (pt) | 2011-09-12 | 2020-11-30 | Boehringer Ingelheim Animal Health Usa Inc | Composições parasiticidas compreendendo um agente ativo de isoxazolina, método e utilizações das mesmas |
| CN104168900A (zh) | 2012-02-06 | 2014-11-26 | 梅里亚有限公司 | 包含全身性地起作用的活性剂的杀寄生虫口服兽用组合物、方法及其用途 |
| BR112014024833B1 (pt) | 2012-04-04 | 2022-10-04 | Intervet International B.V. | Produto farmacêutico veterinário mastigável macio, processo para sua fabricação e seu uso, bem como uso de pamoato de sódio |
| WO2014090918A1 (en) * | 2012-12-13 | 2014-06-19 | Novartis Ag | Process for the enantiomeric enrichment of diaryloxazoline derivatives |
| JP6581586B2 (ja) * | 2013-12-20 | 2019-09-25 | インターベット インターナショナル ベー． フェー． | イソオキサゾリン組成物および動物における寄生虫侵襲の予防または処置におけるその使用 |
| CA2971296A1 (en) | 2014-12-22 | 2016-06-30 | Intervet International B.V. | Use of isoxazoline compounds for treating demodicosis |
-
2015
- 2015-12-21 CA CA2971296A patent/CA2971296A1/en active Pending
- 2015-12-21 AU AU2015371175A patent/AU2015371175B2/en active Active
- 2015-12-21 PL PL15817303.9T patent/PL3236960T3/pl unknown
- 2015-12-21 ES ES21213190T patent/ES3037078T3/es active Active
- 2015-12-21 DK DK21213190.8T patent/DK4008329T3/da active
- 2015-12-21 PT PT158173039T patent/PT3236960T/pt unknown
- 2015-12-21 FI FIEP15817303.9T patent/FI3236960T3/fi active
- 2015-12-21 PT PT212131908T patent/PT4008329T/pt unknown
- 2015-12-21 ES ES15817303T patent/ES3018234T3/es active Active
- 2015-12-21 DK DK15817303.9T patent/DK3236960T3/da active
- 2015-12-21 PL PL21213190.8T patent/PL4008329T3/pl unknown
- 2015-12-21 CN CN201580069964.4A patent/CN106999475B/zh active Active
- 2015-12-21 US US15/537,547 patent/US20170348286A1/en not_active Abandoned
- 2015-12-21 FI FIEP21213190.8T patent/FI4008329T3/fi active
- 2015-12-21 CN CN202210404756.7A patent/CN114681453A/zh active Pending
- 2015-12-21 RU RU2017126029A patent/RU2709198C2/ru active
- 2015-12-21 EP EP21213190.8A patent/EP4008329B1/en active Active
- 2015-12-21 BR BR112017013286-9A patent/BR112017013286A2/pt not_active Application Discontinuation
- 2015-12-21 EP EP15817303.9A patent/EP3236960B1/en active Active
- 2015-12-21 EP EP25179725.4A patent/EP4599830A3/en active Pending
- 2015-12-21 JP JP2017533378A patent/JP6706262B2/ja active Active
- 2015-12-21 WO PCT/EP2015/080744 patent/WO2016102437A1/en not_active Ceased
-
2018
- 2018-04-04 US US15/944,967 patent/US10799483B2/en active Active
-
2020
- 2020-09-09 US US17/015,263 patent/US20200405692A1/en not_active Abandoned
-
2021
- 2021-06-04 AU AU2021203686A patent/AU2021203686A1/en not_active Abandoned
-
2023
- 2023-08-25 AU AU2023219972A patent/AU2023219972B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| PT3185957T (pt) | Patisiran para utilização no tratamento de amoloidose mediada por transtirretina | |
| DK3590543T3 (da) | Medicinsk forbinding | |
| IL249292A0 (en) | Methods and devices for treating pulmonary edema | |
| EP3205103C0 (en) | INTER AND INTRA UNIFICATION BLOCK COPY | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| DK3231444T3 (da) | Ny behandling | |
| EP3215219C0 (en) | SKIN TREATMENT SYSTEM | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| HRP20182134T1 (hr) | Triazinski spoj i njegova upotreba u medicinske svrhe | |
| IL251904A0 (en) | Apilimod for use in the treatment of melanoma | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| PL3194421T3 (pl) | Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania | |
| PT3134119T (pt) | Tratamento do cancro | |
| HUE046894T2 (hu) | Anamorelinen alapuló gyógyászati kezelések | |
| DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| IL251345A0 (en) | Compositions for use in the treatment of peri-implantitis | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| HUE046209T2 (hu) | Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra | |
| DE112015001144A5 (de) | Therapievorrichtung |